Amylyx Pharmaceuticals (AMLX) Competitors

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking.

Which has more risk & volatility, AMLX or AMPH?

Amylyx Pharmaceuticals has a beta of -0.51, meaning that its stock price is 151% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.

Does the media favor AMLX or AMPH?

In the previous week, Amphastar Pharmaceuticals had 5 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 10 mentions for Amphastar Pharmaceuticals and 5 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.11 beat Amphastar Pharmaceuticals' score of 0.49 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor AMLX or AMPH?

Amphastar Pharmaceuticals received 358 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. However, 66.67% of users gave Amylyx Pharmaceuticals an outperform vote while only 65.99% of users gave Amphastar Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Amylyx Pharmaceuticals	Outperform Votes 34 66.67%	Underperform Votes 17 33.33%
Amphastar Pharmaceuticals	Outperform Votes 392 65.99%	Underperform Votes 202 34.01%

Do insiders and institutionals hold more shares of AMLX or AMPH?

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate AMLX or AMPH?

Amylyx Pharmaceuticals currently has a consensus target price of $7.33, suggesting a potential upside of 100.36%. Amphastar Pharmaceuticals has a consensus target price of $43.50, suggesting a potential upside of 53.01%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Amphastar Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is AMLX or AMPH more profitable?

Amphastar Pharmaceuticals has a net margin of 21.80% compared to Amylyx Pharmaceuticals' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-36.97%	-29.61%
Amphastar Pharmaceuticals	21.80%	26.44%	11.89%

Which has preferable earnings & valuation, AMLX or AMPH?

Amphastar Pharmaceuticals has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	3.71	$49.27M	-$4.44	-0.82
Amphastar Pharmaceuticals	$731.97M	1.85	$137.54M	$3.06	9.29

Summary

Amphastar Pharmaceuticals beats Amylyx Pharmaceuticals on 11 of the 19 factors compared between the two stocks.